Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya, +19

European Journal of Cancer

Real-world SettingMedicinePathologyFirst-line TreatmentMolecular Oncology +6

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Go Saito, Yuko Oya, Yoshihiko Taniguchi, +16

Lung Cancer

Durvalumab Consolidation TherapyMedicineMetronomic TherapyReal-world SurveyBronchial Neoplasm +7

The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment

Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, +10

Lung Cancer

Cancer ImmunosurveillanceMedicineTumor BurdenImmunologyImmune-checkpoint Inhibitor Treatment +5

[An early phase II study of CPT-11 in primary lung cancer].

Hiroyuki Nakai, M. Fukuoka, Kiyoyuki Furuse, +7

PubMed

Health SciencesAdvanced Lung DiseaseMedicinePrimary Lung CancerPathology +11

Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis

Kodai Kawamura, Kazuya Ichikado, Makoto Takaki, +9

SpringerPlus

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki, +19

CHEST Journal

Drug-related Pneumonitis InducedOncologyPerineural InvasionMedicinePathology +8

Comparisons between tumor burden and other prognostic factors that influence survival of patients with non‐small cell lung cancer treated with immune checkpoint inhibitors

Yoshihiko Sakata, Kodai Kawamura, Kazuya Ichikado, +9

Thoracic Cancer

Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility

Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, +19

JAMA Network Open

Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors. Part 3: 7-Methoxy-1-hydroxy-1-substituted Tetraline Derivatives

Hiromichi Itani, Harunobu Ito, Yoshihiko Sakata, +3

Bioorganic & Medicinal Chemistry Letters

Novel Potent Antagonists7-Methoxy-1-hydroxy-1-substituted Tetraline DerivativesMedicineFunctional SelectivityNeuropeptide Receptor +7

Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

Mihoko Imaji, Daichi Fujimoto, Yuki Sato, +19

European Journal of Cancer

Osimertinib RechallengePneumothoraxClinical EpidemiologyPatient SafetyOrthopaedics +2